WO2006030297B1 - Taste masked granules comprising clarithromycin, hydrocolloids and a coating - Google Patents

Taste masked granules comprising clarithromycin, hydrocolloids and a coating

Info

Publication number
WO2006030297B1
WO2006030297B1 PCT/IB2005/002739 IB2005002739W WO2006030297B1 WO 2006030297 B1 WO2006030297 B1 WO 2006030297B1 IB 2005002739 W IB2005002739 W IB 2005002739W WO 2006030297 B1 WO2006030297 B1 WO 2006030297B1
Authority
WO
WIPO (PCT)
Prior art keywords
clarithromycin
hydrocolloids
coating
taste masked
core
Prior art date
Application number
PCT/IB2005/002739
Other languages
French (fr)
Other versions
WO2006030297A1 (en
Inventor
Rajeev Shanker Mathur
Kamal Mehta
Chandrasekaran Prabagaran
Original Assignee
Ranbaxy Lab Ltd
Rajeev Shanker Mathur
Kamal Mehta
Chandrasekaran Prabagaran
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd, Rajeev Shanker Mathur, Kamal Mehta, Chandrasekaran Prabagaran filed Critical Ranbaxy Lab Ltd
Publication of WO2006030297A1 publication Critical patent/WO2006030297A1/en
Publication of WO2006030297B1 publication Critical patent/WO2006030297B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

The present invention relates to taste masked granules comprising a) a core comprising clarithromycin, one or more hydrocolloids, one or more pharmaceutically acceptable excipients (ratio clarithromycin: hydrocolloid- 1: 0.2- 1: 10) b) a coating over the core containing one or more pH dependent polymers that release clarithromycin at a pH above 4.5.

Claims

AMENDED CLAIMS
[received by the International Bureau on 03 March 2006 (03.03.2006) : original claim 27 amended ; claims 1-26 unchanged]
(a) a core comprising clarithromycin and one or more hydrocolloids, wherein clarithromycin and the one or more hydrocolloid are present in a ratio from about 1:0.2 to about 1:10; and (b) a coating over the core comprising one or more pH dependent polymers that release clarithromycin at a pH above 4.5. 27. The method of treating bacterial infections according to claim 26, wherein the pharmaceutical composition further comprises one or more of omeprazole, ansamycin, amoxycillin, tetracycline, chloramphenicol, ciprofloxacin, ethambutol, ritonavir, rifampicin and metronidazole.
AMENDED SHEET (ARTICLE 19)
PCT/IB2005/002739 2004-09-17 2005-09-15 Taste masked granules comprising clarithromycin, hydrocolloids and a coating WO2006030297A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1768/DEL/2004 2004-09-17
IN1768DE2004 2004-09-17

Publications (2)

Publication Number Publication Date
WO2006030297A1 WO2006030297A1 (en) 2006-03-23
WO2006030297B1 true WO2006030297B1 (en) 2006-05-04

Family

ID=35448287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002739 WO2006030297A1 (en) 2004-09-17 2005-09-15 Taste masked granules comprising clarithromycin, hydrocolloids and a coating

Country Status (1)

Country Link
WO (1) WO2006030297A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932634B2 (en) * 2006-06-15 2015-01-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Hydrocolloid carrier beads with inert filler material
FR2935084B1 (en) * 2008-08-19 2011-05-06 Pancosma Sa Pour L Ind Des Produits Biochimiques ADDITIVE FOR ANIMAL FEED AND METHOD FOR PREPARING THE SAME
AU2015254875A1 (en) 2014-05-01 2016-11-17 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US10285908B2 (en) 2014-07-30 2019-05-14 Sun Pharmaceutical Industries Ltd Dual-chamber pack
CN104473881A (en) * 2014-12-24 2015-04-01 湖北华世通潜龙药业有限公司 Bitter masked clarithromycin pellet preparation and preparation method thereof
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500422D0 (en) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
EP1267840B1 (en) * 2000-03-28 2009-06-03 Sandoz AG Granulated particles with masked taste

Also Published As

Publication number Publication date
WO2006030297A1 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
WO2006030297B1 (en) Taste masked granules comprising clarithromycin, hydrocolloids and a coating
WO2005077050A3 (en) Hiv integrase inhibitors
WO2005115398A3 (en) Hiv integrase inhibitors
WO2003061584A3 (en) Novel substituted benzimidazole dosage forms and method of using same
WO2003088897A3 (en) Fab i inhibitors
WO2006083458A3 (en) Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associates conditions
WO2001068096A3 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
WO2002050061A8 (en) Piperazine derivatives for treatment of bacterial infections
WO2007054976A3 (en) Lipid based controlled release pharmaceutical composition
ZA200701629B (en) Gyrase inhibitors and uses thereof
WO2006096173A8 (en) Pharmaceutical compositions and methods for peptide treatment
WO2006116148A3 (en) (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse
WO2007073911A3 (en) Masking the taste of powders
WO2005070390A3 (en) Mitratapide oral solution
WO2007050294A3 (en) Liquid dosage forms having enteric properties of delayed and then sustained release
WO2003099217A3 (en) Methods of treating bacterial infections and diseases associated therewith
WO2005044199A3 (en) Combination of proton pump inhibitor and sleep aid
WO2002062794A3 (en) Compounds
IL172634A0 (en) Agent for inhibiting membrane virus reproduction, method for the production thereof pharmaceutical composition and method for inhibiting viral infections
EP1663959A4 (en) Novel amidine compounds for treating microbial infections
WO2007019098A3 (en) Hiv integrase inhibitors
AU2002356868A1 (en) Methods for the prevention or treatment of bacterial and fungal infections
WO2002072571A3 (en) Pyridinyl pyrazoles useful for the treatment of copd
WO2005118613A3 (en) Antibacterial amide macrocycles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

B Later publication of amended claims

Effective date: 20060303

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase